Jiayue Pharmaceutical

Jiayue Pharmaceutical (嘉越医药) is a clinical-stage biopharmaceutical company headquartered in Guangzhou, China, with major R&D centers in Shanghai and Hangzhou. The company focuses on the development of innovative small molecule therapeutics for oncology, immunology, infectious diseases, and metabolic disorders. Jiayue utilizes a translational medicine platform to accelerate the transition of candidates from discovery to late-stage clinical trials. The company has established a robust pipeline with multiple assets in Phase 2 and Phase 3 development. It is notably recognized for its ROS1 inhibitor program and its partnership with Erasca for RAS-targeted therapies. Jiayue has consistently secured significant venture capital from top-tier Chinese and international investors to advance its mid-to-late stage clinical programs.